#1 Clinical Trials Search in Europe

Ixazomib

Ixazomib, also known by its brand name Ninlaro or research code MLN9708, is an oral proteasome inhibitor being studied in various clinical trials for different types of cancer and autoimmune conditions. This article explores the ongoing research into ixazomib’s potential as a treatment option for multiple myeloma, lymphoma, leukemia, and other diseases.

Table of Contents

What is IXAZOMIB?

IXAZOMIB, also known by its research name MLN9708, is a medication used in the treatment of various blood cancers[1]. It belongs to a class of drugs called proteasome inhibitors, which work by interfering with the way cancer cells process proteins[1]. IXAZOMIB is considered a second-generation proteasome inhibitor, meaning it’s an improved version of earlier drugs in this category[1].

How IXAZOMIB Works

IXAZOMIB works by blocking the action of proteasomes, which are cellular structures that help break down old or damaged proteins in cells. Cancer cells often have higher levels of protein production and breakdown than normal cells. By inhibiting proteasomes, IXAZOMIB causes an accumulation of proteins in cancer cells, leading to cell stress and eventually cell death[1]. This mechanism of action makes IXAZOMIB particularly effective against certain types of blood cancers.

Conditions Treated with IXAZOMIB

IXAZOMIB is used to treat several types of blood cancers and related conditions, including:

  • Multiple Myeloma: A cancer of plasma cells, which are a type of white blood cell[2]
  • Lymphoma: A group of blood cancers that develop in the lymphatic system[1]
  • Systemic Light Chain (AL) Amyloidosis: A rare disease where abnormal proteins build up in organs, causing them to malfunction[3]
  • Acute Lymphoblastic Leukemia: A type of blood cancer that affects white blood cells[4]

IXAZOMIB is often used in patients whose cancer has returned after previous treatments (relapsed) or hasn’t responded well to other therapies (refractory)[3].

How IXAZOMIB is Administered

IXAZOMIB is typically given as an oral medication in the form of capsules. The dosing schedule can vary depending on the specific condition being treated and the treatment plan, but it’s often administered as follows:

  • Once weekly on days 1, 8, and 15 of a 28-day treatment cycle[2]
  • The dose may range from 3 mg to 4 mg, depending on the patient’s condition and how well they tolerate the medication[5]
  • IXAZOMIB is often given in combination with other medications, such as lenalidomide and dexamethasone, to enhance its effectiveness[2]

It’s important to take IXAZOMIB exactly as prescribed by your healthcare provider. The treatment duration can vary, but it may continue for several months or even years, as long as the patient is benefiting from the therapy and not experiencing severe side effects[2].

IXAZOMIB in Clinical Trials

IXAZOMIB has been the subject of numerous clinical trials to evaluate its safety and effectiveness in treating various blood cancers. These trials have investigated:

  • The use of IXAZOMIB in combination with other drugs for newly diagnosed multiple myeloma[5]
  • Its effectiveness in treating relapsed or refractory multiple myeloma[6]
  • The potential of IXAZOMIB as a maintenance therapy to prevent cancer recurrence[2]
  • Its use in treating systemic light chain amyloidosis[3]
  • The safety and efficacy of IXAZOMIB in patients with various types of lymphoma[1]

These clinical trials have helped establish the appropriate dosing, identify potential side effects, and determine the most effective treatment combinations for different conditions[5][6].

Potential Side Effects

Like all medications, IXAZOMIB can cause side effects. Some of the most commonly reported side effects include:

  • Gastrointestinal issues: Nausea, vomiting, diarrhea, and constipation[1]
  • Blood-related effects: Low platelet count (thrombocytopenia), which can increase the risk of bleeding, and low white blood cell count (neutropenia), which can increase the risk of infections[1]
  • Fatigue: Feeling unusually tired or weak[2]
  • Peripheral neuropathy: Numbness, tingling, or pain in the hands and feet[1]
  • Skin rash[2]

It’s important to report any side effects to your healthcare provider, as they can often be managed through dose adjustments or supportive treatments[2].

Effectiveness of IXAZOMIB

Clinical trials have shown that IXAZOMIB can be effective in treating various blood cancers, particularly when used in combination with other medications. Some key findings include:

  • Improved progression-free survival in patients with relapsed or refractory multiple myeloma when combined with lenalidomide and dexamethasone[2]
  • High response rates in newly diagnosed multiple myeloma patients[5]
  • Promising results in treating systemic light chain amyloidosis[3]
  • Potential effectiveness as a maintenance therapy to prevent cancer recurrence[2]

The effectiveness of IXAZOMIB can vary depending on the specific condition being treated, the stage of the disease, and individual patient factors. Your healthcare provider can provide more information about the expected benefits of IXAZOMIB in your particular case[2][5].

Trial Focus Key Findings/Objectives Patient Population Dosing
Multiple Myeloma Maintenance Evaluating progression-free survival and overall survival after autologous stem cell transplant Newly diagnosed multiple myeloma patients 3 mg for first 4 cycles, then 4 mg for remaining cycles
Graft-versus-host Disease Prevention Determining maximum tolerated dose and efficacy in preventing chronic GVHD Patients undergoing allogeneic stem cell transplantation Varying doses (2.3 mg, 3.0 mg, 4.0 mg) based on study phase
Follicular Lymphoma Assessing overall response rate in relapsed/refractory follicular lymphoma Adult patients with relapsed/refractory follicular lymphoma 4, 5.3, and 7 mg doses evaluated
Acute Myeloid Leukemia Evaluating response rates in relapsed/refractory AML with NPM1 mutations Adult patients with relapsed/refractory AML Oral administration on days 1, 4, 8, and 11 of 21-day cycles
Glioblastoma Measuring tumor tissue concentration and safety profile Patients with recurrent glioblastoma undergoing surgery Single dose 3 hours before surgery
Autoimmune Cytopenias Assessing efficacy and safety in refractory autoimmune cytopenias Patients with refractory ITP or AIHA Starting at 3 mg with potential dose escalation

FAQ

  • What is ixazomib and how does it work? Ixazomib is an oral proteasome inhibitor. It works by blocking enzymes that cancer cells need to grow and survive, potentially slowing or stopping the growth of cancer cells.
  • What types of cancer is ixazomib being studied for? Ixazomib is being studied in clinical trials for multiple myeloma, lymphoma, acute myeloid leukemia, and glioblastoma. It's also being investigated for autoimmune conditions like immune thrombocytopenia and autoimmune hemolytic anemia.
  • How is ixazomib administered? Ixazomib is taken orally as a capsule. The dosing schedule varies depending on the specific trial, but it's often given on days 1, 8, and 15 of a 28-day cycle.
  • What are some potential side effects of ixazomib? Common side effects may include nausea, vomiting, diarrhea, constipation, rash, back pain, and peripheral neuropathy. The trials are closely monitoring for any serious adverse events.
  • Is ixazomib approved for use outside of clinical trials? Ixazomib (Ninlaro) is FDA-approved for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received at least one prior therapy. Its use for other conditions is still investigational.

Ongoing Clinical Trials on Ixazomib

  • Study Comparing bb2121 with Standard Treatments for Patients with Relapsed and Refractory Multiple Myeloma

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Norway +1

  • Study on the Effectiveness of Ixazomib, Lenalidomide, and Dexamethasone in Treating Newly Diagnosed Multiple Myeloma in Patients Eligible for Transplant

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland Lithuania Norway Sweden

Glossary

  • Proteasome inhibitor: A type of drug that blocks the action of proteasomes, cellular structures that break down proteins. By interfering with this process, proteasome inhibitors can cause cancer cells to die.
  • Multiple myeloma: A cancer of plasma cells, a type of white blood cell that normally produces antibodies.
  • Graft-versus-host disease (GVHD): A complication that can occur after a stem cell or bone marrow transplant where the donated cells attack the recipient's body.
  • Autologous stem cell transplant: A procedure where a patient's own stem cells are collected, stored, and then returned to them after high-dose chemotherapy.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall survival (OS): The length of time from either the date of diagnosis or the start of treatment that patients are still alive.
  • Acute myeloid leukemia (AML): A type of cancer that affects the blood and bone marrow, characterized by rapid growth of abnormal white blood cells.
  • Glioblastoma: An aggressive type of cancer that occurs in the brain or spinal cord.
  • Follicular lymphoma: A type of non-Hodgkin lymphoma that begins in the lymphatic system.
  • Immune thrombocytopenia (ITP): A blood disorder characterized by a decrease in the number of platelets in the blood.
  • Autoimmune hemolytic anemia (AIHA): A condition where the immune system mistakenly destroys red blood cells.
  • Minimal residual disease (MRD): Small numbers of cancer cells that remain in the body during or after treatment.
  • Peripheral neuropathy: Damage to the nerves outside of the brain and spinal cord, often causing weakness, numbness, and pain in the hands and feet.